Citigroup upgraded biopharmaceutical company

Adolor

( ADLR) to hold from sell, citing a decision from the company's partner

GlaxoSmithKline

(GSK) - Get Report

to continue with a late-stage program for its bowel treatment drug, Entereg. The firm also upped Adolor's stock price target to $10 from $5. Shares were recently adding 41 cents, or 4.8%, to $9.01.

Nabi Biopharmaceuticals

(NABI)

was higher after the company posted a narrower-than-expected fourth-quarter loss late Monday. The company also announced plans to cut its operations into two business units, Nabi Biologics and Nabi Pharmaceuticals. The stock was rising 22 cents, or 4.6%, at $5.05.

On the other hand,

Emisphere Technologies

(EMIS)

tumbled 10.3% after the company attached an addendum to its fourth-quarter and year-end results. The addendum included a note from Emisphere's accountant that raised doubts that the company had the capital resources and ability to operate after September. Emisphere was off 47 cents to $4.10.

Merck

(MRK) - Get Report

inched lower after a jury in New Jersey awarded $20 million in compensatory damages and $27.5 million in punitive damages to plaintiffs against the company in a Vioxx-related personal injury case. Merck was recently down 4 cents, or 0.1%, to $44.25.

Elsewhere,

PDL BioPharma

(PDLI) - Get Report

was gaining 1.6% at $19.43.

Amgen

(AMGN) - Get Report

was higher by 1.4% at $61.54.

King Pharmaceuticals

( KG) was adding 1% at $18.83.

Among losers,

Teva Pharmaceutical

(TEVA) - Get Report

was off 1.5% at $36.06.

Forest Labs

(FRX)

was recently losing 0.9% at $51.65.

Schering-Plough

( SGP) was lower by 0.2% at $23.91.